ArticleBMC gastroenterology2025
Therapeutic regimen of Crohn's disease: effect of Infliximab combined with mesalazine on intestinal flora and inflammatory indexes in patients.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- An Immune Microenvironment-Integrated Intestinal-on-a-Chip Model for Investigating Immunopathogenesis in Inflammatory Bowel Disease.Molecules (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo study the clinical efficacy of infliximab (IFX) in combination with mesalazine in patients with Crohn’s disease (CD).
methodsThis retrospective analysis study included 197 patients with CD who were treated in Haiyan People's Hospital and Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University our hospital between March 2023 and March 2024, and were divided into two groups according to the different treatments recorded in the electronic medical record system: 82 cases in the control group (mesalazine) and 115 cases in the observation group (IFX combined with mesalazine treatment). The intestinal flora (bifidobacteria, Lactobacillus, Enterococcus, Enterobacteriaceae), serum indicators (tumor necrosis factor-α (TNF-α), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), hemoglobin concentration (HGB), platelets (PLT), Th1, Th2, Th1/Th2), major symptoms and stool status (disappearance of abdominal pain, disappearance of diarrhea, stool frequency and stool normalization), clinical efficacy and complication situation were evaluated.
resultsThe number of bifidobacteria and lactobacilli in the observation group was higher than that in the control group, and the difference was statistically significant (P < 0.05); TNF-α, CRP, ESR, PLT, Th1 and Th1/Th2 were lower than those in the control group, but HGB and Th2 were higher than those in the control group, and the difference was statistically significant (P < 0.05); After treatment, the rate of abdominal pain disappearance, diarrhea disappearance and normal stool rate were higher than that of the control group, and the number of stools was lower than that of the control group, with statistically significant differences (P < 0.05); the total clinical effective rate of the observation group (92.17% vs. 80.49%) was higher than that of the control group, with statistically significant difference (P < 0.05); the overall incidence rate of adverse reactions of the observation group (8.70% vs. 7.32%) was higher than that of the control group, but the difference was not statistically significant (P > 0.05).
conclusionIFX combined with mesalazine demonstrates superior clinical efficacy compared to mesalazine monotherapy in patients with Crohn’s disease. This combination effectively improves intestinal microbiota balance, reduces inflammation, modulates immune responses, and alleviates clinical symptoms without significantly increasing adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.